NCT06800391View on ClinicalTrials.gov

Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2029

Conditions
Pseudomyxoma Peritonei
Interventions
COMBINATION_PRODUCT

Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day

Capecitabine (1250 mg/m2 /day) and Cyclophosphamide (50 mg/day) continuous daily dosing. Cycles are to be repeated every 28 days for a total of 6 cycles.

Trial Locations (1)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER